Antibiotic dosing during sustained low-efficiency dialysis: Special considerations in adult critically ill patients

Critical Care Medicine

Volumn 39, Issue 3, 2011, Pages 560-570

  Bogard, Kimberly N ^a,b   Peterson, Nicole T ^d   Plumb, Troy J ^c   Erwin, Michael W ^a   Fuller, Patrick D ^a,b   Olsen, Keith M ^a,b  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

anti infectives; antibiotics; continuous renal replacement therapy; critical care; dialysis; pharmacokinetics; sustained low efficiency dialysis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANIDULAFUNGIN; ANTIBIOTIC AGENT; CARBAPENEM; CASPOFUNGIN; CIPROFLOXACIN; DAPTOMYCIN; DORIPENEM; ECHINOCANDIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MICAFUNGIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE; TOBRAMYCIN; UREA; VANCOMYCIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD FILTER; BLOOD FLOW VELOCITY; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE CLEARANCE; CRITICAL ILLNESS; DIALYSATE; DIALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 79952184590     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318206c3b2     Document Type: Review

References (67)

1. Bellomo R, Roncom C, Kellum JA, et al: Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-R212.
2. Lameire N, Van Biesen W, Vanholder R: Acute renal failure. Lancet 2005; 365: 417-430. (Pubitemid 40179230)
3. Joy MS, Matzke GR, Armstrong DK, et al: A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998; 32:362-375. (Pubitemid 28120354)
4. Kramer P, Wigger W, Reiger J, et al: [Arteriovenous haemofiltration: A new and simple method for treatment of over-hydrated patients resistant to diuretics]. Klin Wochenschr 1977; 55:1121-1122. (Pubitemid 8207270)
5. Marshall MR, Golper TA, Shaver MJ, et al: Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 2001; 60:777-785. (Pubitemid 32678922)
6. Salahudeen AK, Kumar V, Madan N, et al: Sustained low efficiency dialysis in the continuous mode (C-SLED): dialysis efficacy, clinical outcomes, and survival predictors in critically ill cancer patients. Clin J Am Soc Nephrol 2009; 4:1338-1346.
7. Veltri MA, Neu AM, Fivush BA, et al: Drug dosing during intermittent hemodialysis and continuous renal replacement therapy. Special considerations in pediatric patients. Pediatr Drugs 2004; 6:45-65.
8. Schetz M: Drug dosing in continuous renal replacement therapy: General rules. Curr Opin Crit Care 2007; 13:645-651. (Pubitemid 350059527)
9. Mueller BA, Pasko DA, Sowinski KM: Higher renal replacement therapy dose delivery in- fluences on drug therapy. Artif Organs 2003; 27:808-814. (Pubitemid 37108621)
10. Choi G, Gomersall CD, Tian Q, et al: Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 37:2268-2282.
11. Heintz BH, Matzke GR, Dager WE: Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29:562-577.
12. Mehta R: Supportive therapies: Intermittent hemodialysis, continuous renal replacement therapies, and peritoneal dialysis. In: Atlas of Disease of the Kidney. Schrier R (Ed). Philadelphia, PA, Current Medicine, 1998, pp 1-16.
13. Huang Z, Letteri JJ, Clark WR, et al: Operational characteristics of continuous renal replacement modalities used for critically ill patients with acute kidney injury. Int J Artif Organs 2008; 31:525-534.
14. Davenport A: Renal replacement therapy in acute kidney injury: Which method to use in the intensive care unit? Saudi J Kidney Dis Transpl 2008; 19:529-536.
15. Marshall MR, Golper TA, Shaver MJ, et al: Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. Am J Kidney Dis 2002; 39:556-570. (Pubitemid 34194632)
16. Kumar VA, Craig M, Depner TA, et al: Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 2000; 36:294-300. (Pubitemid 30485837)
17. Marshall MR, Golper TA: Sustained low effi- ciency or extended daily dialysis. In: UpTo- Date, Post TW (Ed). Waltham, MA, UpTo- Date, 2010.
18. Marshall MR, Ma T, Galler D, et al: Sustained low-efficiency daily dialfiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: Towards an adequate therapy. Nephrol Dial Transplant 2004; 19: 877-884. (Pubitemid 38455659)
19. Scott MK, Mueller BA, Clark WR: Vancomycin mass transfer characteristics of high-flux cellulosic dialysers. Nephrol Dial Transplant 1997; 12:2467-2653.
20. Schaedeli F, Uehlinger DE: Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis. Clin Pharmacol Ther 1998; 63:26-38. (Pubitemid 28070183)
21. Mushatt DM, Mihm LB, Dreisbach AW, et al: Antibiotic dosing in slow extended dialysis. Clin Infect Dis 2009; 49:433-437.
22. Rybak MJ: The efficacy and safety of daptomycin: First in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect 2006; 12(Suppl 1):S24-S32.
23. Dvorchik B, Sica D, Gehr T: Pharmacokinetics and safety of single-dose daptomycin in subjects with graded renal insufficiency and end-stage renal disease. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 2002, Abstract A-1387.
24. Wagner CC, Steiner I, Zeitlinger M: Daptomycin elimination by CVVH in vitro: Evaluation of factors influencing sieving and membrane adsorption. Int J Clin Pharmacol Ther 2009; 47:178-186.
25. Burkhardt O, Joukhadar C, Traunmü ller F, et al: Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2007; 60:224-225.
26. Kielstein JT, Eugbers C, Bode-Boeger SM, et al: Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol Dial Transplant 2010; 25: 1537-1541.
27. Dvorchik B, Arbeit RD, Chung J, et al: Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004; 48: 2799-2807. (Pubitemid 38989139)
28. Roberts JA, Lipman J: Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37:840-851; quiz 859.
29. Drusano GL, Ambrose PG, Bhavnani SM, et al: Back to the future: Using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45:753-760. (Pubitemid 47378891)
30. Trotman RL, Williamson JC, Shoemaker DM, et al: Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41: 1159-1166. (Pubitemid 41429480)
31. Begg EJ, Barclay ML, Duffull SB: A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39:605-609.
32. Roberts JA, Field J, Visser A, et al: Using population pharmacokinetics to determine gentamicin dosing during extended daily dia- filtration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother 2010; 54:3635-3640.
33. Rea RS, Capitano B, Bies R, et al: Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30:674-681.
34. Dasta JF, Armstrong DK: Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16: 327-330.
35. Triginer C, Izquierdo I, Fernández R, et al: Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990; 16:303-306. (Pubitemid 20253465)
36. Gustavo L, Castañ eda-Hernández G: Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit 1997; 19:271-276.
37. Marik PE: Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anesth Intensive Care 1993; 21:172-173. (Pubitemid 23132762)
38. Manley HJ, Bailie GR, McClaran ML, et al: Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int 2003; 63:1072-1078. (Pubitemid 36315586)
39. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; updated January, 2011. Available at: http://www.clinicalpharmacology. com. Accessed September 5, 2010.
40. Rybak M, Lomaestro B, Rotschafer JC, et al: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82-98.
41. Rybak MJ: The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42:S35-S39. (Pubitemid 41832063)
42. Pallotta KE, Manley HJ: Vancomycin use in patients requiring hemodialysis: A literature review. Semin Dial 2008; 21:63-70.
43. Ariano RE, Fine A, Sitar DS, et al: Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 2005; 46:681-687. (Pubitemid 41383946)
44. Pai AB, Pai MP: Vancomycin dosing in high flux hemodialysis: A limited-sampling algorithm. Am J Health Syst Pharm 2004; 61: 1812-1816. (Pubitemid 39481362)
45. DelDot ME, Lipman J, Tett SE: Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Br J Clin Pharmacol 2004; 58: 259-268. (Pubitemid 39209059)
46. Kielstein JT, Czock D, Schöpke T, et al: Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34:51-56. (Pubitemid 43032379)
47. Ahern JW, Lai C, Rebuck JA, et al: Experience with vancomycin in patients receiving slow low-efficiency dialysis. Hosp Pharm 2004; 39: 138-143. (Pubitemid 38197502)
48. Zhanel GG, Wiebe R, Dilay L, et al: Comparative review of the carbapenems. Drugs 2007; 67:1027-1052. (Pubitemid 46744477)
49. Mistry GC, Majumdar AK, Swan S, et al: Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. J Clin Pharmacol 2006; 46:1128-1138. (Pubitemid 44387412)
50. Burkhardt O, Hafer C, Langhoff A, et al: Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 2009; 24:267-271.
51. Adembri C, Fallani S, Cassetta MI, et al: Linezolid pharmacokinetics/ pharmacodynamic profile in critically ill septic patients: Intermittent versus continuous infusion. Int J Antimicrob Agents 2008; 31:122-129.
52. Moellering RC: Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135-142.
53. Bain KT, Wittbrodt ET: Linezolid for the treatment of resistant gram-positive cocci. Ann Pharmacother 2001; 35:566-575. (Pubitemid 32428132)
54. Brier ME, Stalker DJ, Aronoff GR, et al: Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47:2775-2780. (Pubitemid 37040247)
55. Fiaccadori E, Maggiore U, Rotelli C, et al: Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transplant 2006; 21: 1402-1406.
56. Mauro LS, Peloquin CA, Schmude K, et al: Clearance of linezolid via continuous venous hemodiafiltration. Am J Kidney Dis 2006; 47:e83-e86. (Pubitemid 43767317)
57. Fiaccadori E, Maggiore U, Rotelli C, et al: Removal of linezolid by conventional intermittent hemodialysis, sustained low-effi- ciency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32:2437-2442. (Pubitemid 39648225)
58. Wright DH, Brown GH, Peterson ML, et al: Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-683.
59. Olsen KM, Gentry-Nielsen M, Yue M: Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother 2006; 50: 210-219. (Pubitemid 43042923)
60. Czock D, Hü sig-Linde C, Langhoff A, et al: Pharmacokinetics of moxifloxacin and levo- floxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 2006; 1:1263-1268.
61. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 2006; 63: 1693-1703. (Pubitemid 44413505)
62. Merck: Caspofungin [package insert]. Whitehouse Station, NJ, Merck, February 2005.
63. Astellas Pharma US: Micafungin [package insert]. Deerfield, IL, Astellas Pharma US, April 2005.
64. Pfizer: Eraxis [package insert]. New York, NY, Pfizer, February 2006.
65. Burkhardt O, Kaever V, Burhenne H, et al: Extended daily dialysis does not affect the pharmacokinetics of anidulafungin. Int J Antimicrob Chemother 2009; 34:282-283.
66. Awdishu L: Drug issues in renal replacement therapies. In: Pharmacotherapy Self-Assessment Program. Sixth Edition. Kansas City, MO, American College of Clinical Pharmacy, 2007.
67. Khan E, Huggan P, Celi L, et al: Sustained low-efficiency dialysis with filtration (SLEDD-f) in the management of acute sodium valproate intoxication. Hemodial Int 2008; 12:211-214 (Pubitemid 351494273)